Cybin.com Have just had their R&D Day Briefing
On November 30th, 2023

Who are Cybin?

Cybin are developing Novel Second-Generation Psychedelics based on Psilocybin, DMT, MDMA with improved bioavailability.

Cybin have:

3 active drug programs targeting Major Depressive Disorder (CYB003), Alcohol Use Disorder (CYB003), Generalized Anxiety Disorder (CYB004) and Neuroinflammation (CYB005).

250+ pre-clinical studies completed and progressing lead programs toward FDA IND filings.

>50 granted or pending patent applications filed across 6 patent families.  

Trial Results

Cybin has reported positive topline data from the Phase II clinical trial of its deuterated psilocybin analogue, CYB003, to potentially treat major depressive disorder (MDD).

The trial analysed the safety and efficacy of CYB003.

According to the trial findings, a quick and clinically significant decline in depression symptoms was reported following treatment with a single dose of the therapy.

Furthermore, a significant incremental benefit was observed after the administration of a second dose.

The trial met the primary efficacy endpoint with a mean -14 point difference in the Montgomery-Asberg Depression Rating Scale (MADRS) score from baseline between a 12mg dose of CYB003 compared to placebo at three weeks.

In the trial, 79% of participants responded to treatment while 79% were in remission from depression following treatment with two doses of the analogue at six weeks.